Medical devices bearing the European CE mark will continue to be accepted in Great Britain on an indefinite basis, the government confirmed on 21 October. The decision removes the prospect of a fixed end date for recognition, but it does not remove domestic obligations for companies placing devices on the market or the UK’s separate UKCA route.
The change applies to Great Britain — England, Scotland and Wales — and concerns devices certified under the EU Medical Devices Regulation and the EU In Vitro Diagnostic Medical Devices Regulation. The government also intends to align transitional arrangements for older devices certified under the previous EU Medical Devices Directive with the European Union’s transition timetable. Northern Ireland operates under a different regulatory framework, so the announcement should not be read as changing its rules.
What changes for suppliers
CE marking is a conformity mark used for products assessed under applicable European requirements. Before this decision, manufacturers faced a gradually narrowing window in which certain CE-marked devices could continue to be placed on the Great Britain market. Indefinite recognition means that manufacturers whose products meet the relevant EU requirements will not need to obtain a second, UK-specific product approval solely because the current recognition period expires.
The government says more than 90 per cent of medical devices registered for use in Great Britain currently carry a CE mark. That share helps explain why the policy has direct implications for the range of equipment and diagnostics available to health services. The government’s stated rationale is to avoid duplicated assessment, support continuity of supply and give manufacturers greater certainty when planning investment and product availability. These are policy aims, not a guarantee that every device will remain available or that supply problems cannot arise for other reasons.
Recognition of the product mark does not amount to deregulation. Manufacturers must still meet domestic requirements, including appointing a UK responsible person where required and registering devices with the Medicines and Healthcare products Regulatory Agency. Post-market surveillance duties also remain: companies must monitor products after they are placed on the market and report relevant safety issues. The agency retains responsibility for oversight of devices sold in the UK and can act on safety concerns.
The UKCA mark continues as the domestic conformity route for devices placed on the Great Britain market. The government says that route is being modernised through planned legislation, while it also intends to seek powers for a future licensing approach. Those are separate strands of reform; the announcement does not say that UKCA has been abolished or that the future licensing system is already in force.
Consultation and remaining questions
The decision follows a consultation held from 16 February to 10 April 2026, which received 1,056 responses. A majority supported indefinite recognition for devices certified under the newer EU rules, citing reduced duplication and the prospect of maintaining access to technology. Some respondents raised concerns about oversight, accountability and the ability to assure safety independently. The government says it will proceed with legislative changes, meaning the policy’s announced direction should be distinguished from the detailed legal implementation still to come.
For patients and clinicians, the immediate significance is regulatory continuity rather than a newly authorised treatment or a change to clinical guidance. The announcement does not assess the safety or effectiveness of any particular product. Its effect is to preserve an established route by which eligible CE-marked products can reach Great Britain, alongside UKCA, while retaining local registration and safety-monitoring requirements.
Implementation details will matter. Manufacturers will need to establish that their products fall within the recognised certification categories and continue to meet applicable Great Britain obligations. Health services, in turn, will still make purchasing and clinical decisions under their usual processes. The government has said it will engage with patient groups as the arrangements are implemented; the precise legal timetable for the promised changes was not specified in the announcement.
